Adjuvant Ovarian Function Suppression and Cognitive Function in Women with Breast Cancer

Overview

Journal Br J Cancer

Specialty Oncology

Date 2016 Apr 20

PMID 27092785

Citations 17

Authors

Kelly-Anne Phillips

Meredith M Regan

Karin Ribi

Prudence A Francis

Fabio Puglisi

Meritxell Bellet

Simon Spazzapan

Per Karlsson

Daniel R Budman

Khalil Zaman

Ehtesham A Abdi

Susan M Domchek

Yang Feng

Karen N Price

Alan S Coates

Richard D Gelber

Paul Maruff

Frances Boyle

John F Forbes

Tim Ahles

Gini F Fleming

Jurg Bernhard

Affiliations

Soon will be listed here.

Abstract

Background: To examine the effect on cognitive function of adjuvant ovarian function suppression (OFS) for breast cancer.

Methods: The Suppression of Ovarian Function (SOFT) trial randomised premenopausal women with hormone receptor-positive breast cancer to 5 years adjuvant endocrine therapy with tamoxifen+OFS, exemestane+OFS or tamoxifen alone. The Co-SOFT substudy assessed objective cognitive function and patient reported outcomes at randomisation (T0), and 1 year later (T1); the primary endpoint was change in global cognitive function, measured by the composite objective cognitive function score. Data were compared for the pooled tamoxifen+OFS and exemestane+OFS groups vs the tamoxifen alone group using the Wilcoxon rank-sum test.

Results: Of 86 participants, 74 underwent both T0 and T1 cognitive testing; 54 randomised to OFS+ either tamoxifen (28) or exemestane (26) and 20 randomised to tamoxifen alone. There was no significant difference in the changes in the composite cognitive function scores between the OFS+ tamoxifen or exemestane groups and the tamoxifen group (mean±s.d., -0.21±0.92 vs -0.04±0.49, respectively, P=0.71, effect size=-0.20), regardless of prior chemotherapy status, and adjusting for baseline characteristics.

Conclusions: The Co-SOFT study, although limited by small samples size, provides no evidence that adding OFS to adjuvant oral endocrine therapy substantially affects global cognitive function.

Citing Articles

Long-term health-related quality of life among adolescent and young adult breast cancer survivors.

Vrancken Peeters N, Kerklaan R, Vlooswijk C, Bijlsma R, Kaal S, Tromp J Qual Life Res. 2025; .

PMID: 39982594 DOI: 10.1007/s11136-025-03914-1.

Ovarian Suppression: Early Menopause and Late Effects.

Molinelli C, Jacobs F, Nader-Marta G, Borea R, Scavone G, Ottonello S Curr Treat Options Oncol. 2024; 25(4):523-542.

PMID: 38478329 PMC: 10997548. DOI: 10.1007/s11864-024-01190-8.

Ovarian Suppression: Early Menopause, Late Effects.

Goldberg C, Greenberg M, Noveihed A, Agrawal L, Omene C, Toppmeyer D Curr Oncol Rep. 2024; 26(5):427-438.

PMID: 38305992 DOI: 10.1007/s11912-023-01491-5.

Efficacy and safety of diphereline 11.25 mg, microrelin 11.25 mg, and microrelin 3.75 mg in premenopausal patients with breast cancer: a non-inferiority randomized clinical trial.

Najafi S, Ansari M, Omidi Z, Olfatbakhsh A, Moghadam S, Hashemi E BMC Cancer. 2023; 23(1):1093.

PMID: 37950162 PMC: 10638790. DOI: 10.1186/s12885-023-11614-7.

Long-Term Cognitive Dysfunction in Cancer Survivors.

Orszaghova Z, Mego M, Chovanec M Front Mol Biosci. 2021; 8:770413.

PMID: 34970595 PMC: 8713760. DOI: 10.3389/fmolb.2021.770413.

References

Craig M, Fletcher P, Daly E, Rymer J, Cutter W, Brammer M . Gonadotropin hormone releasing hormone agonists alter prefrontal function during verbal encoding in young women. Psychoneuroendocrinology. 2007; 32(8-10):1116-27. DOI: 10.1016/j.psyneuen.2007.09.009. View

Collie A, Darby D, Maruff P . Computerised cognitive assessment of athletes with sports related head injury. Br J Sports Med. 2001; 35(5):297-302. PMC: 1724391. DOI: 10.1136/bjsm.35.5.297. View

Coates A, Winer E, Goldhirsch A, Gelber R, Gnant M, Piccart-Gebhart M . Tailoring therapies--improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015. Ann Oncol. 2015; 26(8):1533-46. PMC: 4511219. DOI: 10.1093/annonc/mdv221. View

Broadbent D, Cooper P, Fitzgerald P, Parkes K . The Cognitive Failures Questionnaire (CFQ) and its correlates. Br J Clin Psychol. 1982; 21(1):1-16. DOI: 10.1111/j.2044-8260.1982.tb01421.x. View

Hermelink K, Henschel V, Untch M, Bauerfeind I, Lux M, Munzel K . Short-term effects of treatment-induced hormonal changes on cognitive function in breast cancer patients: results of a multicenter, prospective, longitudinal study. Cancer. 2008; 113(9):2431-9. DOI: 10.1002/cncr.23853. View

Scherling C, Collins B, MacKenzie J, Bielajew C, Smith A . Prechemotherapy differences in response inhibition in breast cancer patients compared to controls: a functional magnetic resonance imaging study. J Clin Exp Neuropsychol. 2012; 34(5):543-60. DOI: 10.1080/13803395.2012.666227. View

Sherwin B . Estrogen and cognitive functioning in women: lessons we have learned. Behav Neurosci. 2011; 126(1):123-7. PMC: 4838456. DOI: 10.1037/a0025539. View

Grigorova M, Sherwin B, Tulandi T . Effects of treatment with leuprolide acetate depot on working memory and executive functions in young premenopausal women. Psychoneuroendocrinology. 2006; 31(8):935-47. DOI: 10.1016/j.psyneuen.2006.05.004. View

Schagen S, Muller M, Boogerd W, Mellenbergh G, van Dam F . Change in cognitive function after chemotherapy: a prospective longitudinal study in breast cancer patients. J Natl Cancer Inst. 2006; 98(23):1742-5. DOI: 10.1093/jnci/djj470. View

10.

Phillips K, Aldridge J, Ribi K, Sun Z, Thompson A, Harvey V . Cognitive function in postmenopausal breast cancer patients one year after completing adjuvant endocrine therapy with letrozole and/or tamoxifen in the BIG 1-98 trial. Breast Cancer Res Treat. 2010; 126(1):221-6. PMC: 3044608. DOI: 10.1007/s10549-010-1235-y. View

11.

Buwalda B, Schagen S . Is basic research providing answers if adjuvant anti-estrogen treatment of breast cancer can induce cognitive impairment?. Life Sci. 2013; 93(17):581-8. DOI: 10.1016/j.lfs.2012.12.012. View

12.

Thewes B, Meiser B, Duric V, Stockler M, Taylor A, Stuart-Harris R . What survival benefits do premenopausal patients with early breast cancer need to make endocrine therapy worthwhile?. Lancet Oncol. 2005; 6(8):581-8. DOI: 10.1016/S1470-2045(05)70254-0. View

13.

Ryan J, Scali J, Carriere I, Amieva H, Rouaud O, Berr C . Impact of a premature menopause on cognitive function in later life. BJOG. 2014; 121(13):1729-39. DOI: 10.1111/1471-0528.12828. View

14.

Janelsins M, Kesler S, Ahles T, Morrow G . Prevalence, mechanisms, and management of cancer-related cognitive impairment. Int Rev Psychiatry. 2014; 26(1):102-13. PMC: 4084673. DOI: 10.3109/09540261.2013.864260. View

15.

Hutchinson A, Hosking J, Kichenadasse G, Mattiske J, Wilson C . Objective and subjective cognitive impairment following chemotherapy for cancer: a systematic review. Cancer Treat Rev. 2012; 38(7):926-34. DOI: 10.1016/j.ctrv.2012.05.002. View

16.

Burstein H, Temin S, Anderson H, Buchholz T, Davidson N, Gelmon K . Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: american society of clinical oncology clinical practice guideline focused update. J Clin Oncol. 2014; 32(21):2255-69. PMC: 4876310. DOI: 10.1200/JCO.2013.54.2258. View

17.

Falleti M, Maruff P, Collie A, Darby D, McStephen M . Qualitative similarities in cognitive impairment associated with 24 h of sustained wakefulness and a blood alcohol concentration of 0.05%. J Sleep Res. 2003; 12(4):265-74. DOI: 10.1111/j.1365-2869.2003.00363.x. View

18.

Bernhard J, Luo W, Ribi K, Colleoni M, Burstein H, Tondini C . Patient-reported outcomes with adjuvant exemestane versus tamoxifen in premenopausal women with early breast cancer undergoing ovarian suppression (TEXT and SOFT): a combined analysis of two phase 3 randomised trials. Lancet Oncol. 2015; 16(7):848-58. PMC: 4562429. DOI: 10.1016/S1470-2045(15)00049-2. View

19.

Mendoza T, Wang X, Cleeland C, Morrissey M, Johnson B, Wendt J . The rapid assessment of fatigue severity in cancer patients: use of the Brief Fatigue Inventory. Cancer. 1999; 85(5):1186-96. DOI: 10.1002/(sici)1097-0142(19990301)85:5<1186::aid-cncr24>3.0.co;2-n. View

20.

Schilder C, Seynaeve C, Beex L, Boogerd W, Linn S, Gundy C . Effects of tamoxifen and exemestane on cognitive functioning of postmenopausal patients with breast cancer: results from the neuropsychological side study of the tamoxifen and exemestane adjuvant multinational trial. J Clin Oncol. 2010; 28(8):1294-300. DOI: 10.1200/JCO.2008.21.3553. View